Description
Velmanase alfa is indicated for the treatment of the non-central nervous system manifestations of alpha-mannosidosis. Velmanase alfa was approved for medical use in the European Union in March 2018, and in the United States in February 2023. Velmanase alfa is the first enzyme replacement therapy approved in the US for the treatment of the non-central nervous system manifestations of alpha-mannosidosis.
Get Access to LAMZEDE (velmanase alfa-tycv) In India
Medvitaz Pharma is equipped to facilitate the distribution of LAMZEDE (velmanase alfa-tycv) (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication LAMZEDE (velmanase alfa-tycv) or the generic version “velmanase alfa-tycv” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.